Nasdaq · Biotech stocks database
IMCC — IM Cannabis Corp. ☆
IMCC (IM Cannabis Corp.) stock: $0.64, $1.1M market cap, $1.9M cash, $9.9M EV, $0.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are an international cannabis company focused on the importation, distribution and sale of medical cannabis products to medical patients in Israel and Germany. Following the regulatory reforms affecting cannabis access in Germany on April 1, 2024, the cannabis market has experienced growth, especially within the medical sector, as access for new patients has become easier.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $1.9M Debt $10.8M Net cash -$8.8M Enterprise value $9.9M Basic shares 0.6M shares Fully diluted shares 0.6M shares Fully diluted market cap $0.4M Cash per share $3.16
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading IMCC daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.